Alivus
Live Price
Recent news and updates for ALIVUS will appear here soon.
"Robust technical setup for ALIVUS with strong AI conviction. The bullish trend in the healthcare space is accelerating while RSI at 58 suggests there is still significant room for upside before reaching overbought territory."
Verified by Stockmo Intelligence Grid
Citing cross-referenced internal documents and market technicals
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
As of the latest market session, Alivus (ALIVUS) is trading at ₹1,160, representing a move of 5.87% from the previous close.
Alivus is listed and traded under the ticker symbol ALIVUS on the National Stock Exchange of India (NSE) and Bombay Stock Exchange (BSE).
Today, Alivus's stock price moved by 5.87%. Long-term growth trends depend on company financials, technical moving averages, and sector momentum in the Healthcare industry.
Our proprietary AI Momentum engine calculates a 83% bullish probability for ALIVUS stock over the next 3-5 days. View the live interactive chart on Stockmo to see dynamic technical forecasting.
Over the past 52 weeks, Alivus shares reached a high of ₹1,193.9 and hit a low of ₹819.
ALIVUS exhibits standard volatility for a Healthcare stock, with an average daily trading volume of 2,37,291 shares. Detailed technical beta indicators are available on the Stockmo charting engine.
Alivus has a market capitalization of ₹14213.23 Cr, designating its size class inside the Healthcare sector.
Alivus has a current dividend yield of 43.00%. Companies may adjust payout ratios depending on quarterly earnings growth and reinvestment opportunities.
Alivus's trailing Price-to-Earnings (P/E) ratio is 23.60. This indicates how much investors are willing to pay for every rupee of the company's annual net earnings.
You can purchase Alivus (ALIVUS) shares through any SEBI-registered stockbroker (such as Kite/Zerodha, Groww, or Angel One) by funding your trading account and executing a buy order on the NSE or BSE.
Alivus's financial health, solvency, growth, and quality metrics are tracked using our proprietary Multibagger V2 score. You can explore ALIVUS's detailed 5-tier financial scorecard and compare it with market competitors on the Stockmo Multibagger Screener page.
Institutional order blocks and pristine support/resistance triggers for ALIVUS are monitored in real-time. View live technical entry levels, stop loss bounds, and target prices on our interactive Supply & Demand Trading Engine or scan entire market segments using the Basket Scanner.
Alivus operates inside the Healthcare sector. You can analyze sector-wide trends, relative strengths, and locate top emerging leaders in this space using our Sector Analysis Hub.